Medicines

Discover all available medicines and treatments

Tepotinib: Uses, Interactions, and Clinical Data

Tepotinib

Brand: Tepmetko

Kinase Inhibitor, Antineoplastic Agent

AntineoplasticTargeted Therapy

ApprovedPrescription Only

Overview

Tepotinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mesenchymal-epithelial transition (MET) exon 14 skipping alteration. It is an oral medication that targets the MET receptor tyrosine kinase, inhibiting its activity and thus hindering the growth and spread of cancer cells that rely on MET signaling. Tepotinib belongs to the class of targeted therapy medications.

Primary Use

Tepotinib is used to treat metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations.

Pharmacokinetics

Approximately 4 hours

Onset

48-52 hours

Half-Life

500 mg

Max Dose

Liver (CYP3A4 and CYP1A2)

Metabolism

Clinical Applications

Approved Indications

Non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations

Off-Label Uses

Other MET-driven cancers (e.g., gastric cancer, glioblastoma)

Acquired resistance to other tyrosine kinase inhibitors (TKIs)

Side Effects

Anorexia

Diarrhea

Rash

Interstitial lung disease

Dermatitis

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)

High

Outcome:

Increased tepotinib exposure

Mechanism:

Inhibition of tepotinib metabolism

Moderate CYP3A4 inhibitors (e.g., erythromycin)

Moderate

Outcome:

Increased tepotinib exposure

Mechanism:

Partial inhibition of tepotinib metabolism

Foods high in fat

Low

Outcome:

Slightly increased tepotinib absorption

Mechanism:

Enhanced solubility in lipids

AI Predictions & Insights

Innovation Forecast

Most likely new formulation: Combination therapy with other targeted agents (2025-2028, 70% confidence)

Regulatory Outlook

Based on clinical trial data and post-marketing surveillance, there is a high likelihood (>80%) that tepotinib will maintain its current approval status for MET exon 14 skipping NSCLC.

Medicines

Tepotinib

Overview

Primary Use

Pharmacokinetics

Clinical Applications

Approved Indications

Off-Label Uses

Side Effects

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)

Moderate CYP3A4 inhibitors (e.g., erythromycin)

Foods high in fat

AI Predictions & Insights

Classification & Chemical Information

Primary Classification

Chemical Class